|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,228.90 INR | -1.28% |
|
+4.14% | -8.67% |
| 12/02 | Concord Biotech Limited, Q3 2026 Earnings Call, Feb 12, 2026 | |
| 11/02 | Concord Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 | CI |
Main competitors
| Revenues (N-1) | Net Margin (N-1) | EBIT Margin (N-1) | ROE (N-1) | ROA (N-1) | Leverage (N-1) | ||
|---|---|---|---|---|---|---|---|
| 14Cr | 30.97% | 37.66% | 22.26% | 19.9% | -0.63x | ||
| 1.43TCr | 31.41% | 34.05% | 16.13% | 12.48% | -1.09x | ||
| 636.92Cr | 17.31% | 13.59% | 11.21% | 6.48% | 0.99x | ||
| 1.56TCr | 19.3% | 28.72% | 16.36% | 7.75% | 1.74x | ||
| 307.82Cr | 23.82% | 29.03% | 10.45% | 6.49% | 0.1x | ||
| 989.06Cr | 13.07% | 28.69% | 7.39% | 4.5% | 0.68x | ||
| 129.08Cr | -1% | -8.02% | -0.74% | -0.45% | -11.4x | ||
| 424.12Cr | 0.77% | 9.76% | 5.27% | 3.72% | -4.29x | ||
| 323.6Cr | -110.04% | -121.91% | -28.77% | -21.87% | 1.87x | ||
| 235.17Cr | 14.93% | 22.42% | 10.9% | 5.41% | 1.59x | ||
| 22Cr | -241.44% | -267.22% | 35.11% | -73.11% | -1.77x | ||
| 6.96Cr | 59.01% | 24.7% | 28.77% | 18.72% | -6.16x | ||
| 285.39Cr | 14.96% | 16.97% | 8.05% | 6.17% | -0.93x | ||
| 1.09Cr | -2,957.71% | -3,477.43% | -33.47% | - | 3.99x | ||
| 39Cr | -74.47% | -72.74% | -231.63% | -49.66% | 0.49x | ||
| 746.7Cr | 2.18% | 18.81% | 2.79% | 0.74% | 5.16x | ||
| 29Cr | 30.69% | 22.61% | 10.34% | - | -8.45x | ||
| 124.78Cr | 22.95% | 28.06% | 14.19% | 8.74% | 0.28x | ||
| 31Cr | 4.73% | 4.18% | 0.85% | - | -5.29x | ||
| Average | 386.07Cr | -163.08% | -190.95% | -4.98% | -2.75% | -1.22x | |
| Weighted average by Cap. | 713.45Cr | -68.5% | -80.26% | 4.9% | 2.51% | -0.68x |
- Stock Market
- Equities
- CONCORDBIO Stock
- Sector Concord Biotech Limited
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















